Maged  Shenouda net worth and biography

Maged Shenouda Biography and Net Worth

Maged Shenouda has been our Chief Financial Officer since January 2020. He was also our director from November 2015 to January 2020. During his time as a director with the Company Mr. Shenouda was a member of the Audit Committee and Compensation Committee, and Chairman of the Corporate Governance and Nominating Committee. Mr. Shenouda has over 25 years of biotechnology and equity research experience. From September 2017 to November 2019, Mr. Shenouda was the Chief Financial Officer of AzurRx Biopharma, Inc. where he also served as a Director from October 2015 to October 2019. Prior to this Mr. Shenouda was the Head of Business Development and Licensing at Retrophin, Inc. from January 2014 to November 2014. Prior to that, he spent the bulk of his career as an equity analyst. He has held senior level positions at UBS, JP Morgan and Stifel Nicolaus, covering a broad range of small and large capitalization biotechnology companies. Mr. Shenouda started his sell-side equity research career at Citigroup and Bear Stearns where his coverage universe focused on U.S and European pharmaceutical companies. Before entering Wall Street, he was a management consultant with PricewaterhouseCoopers Pharmaceutical Consulting practice and also spent time in pharmaceutical sales, having worked as a hospital representative and managed care specialist for Abbott Laboratories Pharmaceutical Products Division. He earned a B.S. in Pharmacy from St. John’s University and is a registered pharmacist in New Jersey and California. He also received an M.B.A from Rutgers Graduate School of Management. Provided by Tagnifi.

What is Maged Shenouda's net worth?

The estimated net worth of Maged Shenouda is at least $50,288.08 as of January 29th, 2024. Mr. Shenouda owns 13,028 shares of Relmada Therapeutics stock worth more than $50,288 as of April 25th. This net worth evaluation does not reflect any other investments that Mr. Shenouda may own. Additionally, Mr. Shenouda receives a salary of $1,010,000.00 as CFO at Relmada Therapeutics. Learn More about Maged Shenouda's net worth.

How old is Maged Shenouda?

Mr. Shenouda is currently 60 years old. There are 5 older executives and no younger executives at Relmada Therapeutics. The oldest executive at Relmada Therapeutics is Dr. Richard M. Mangano, Consultant, who is 74 years old. Learn More on Maged Shenouda's age.

What is Maged Shenouda's salary?

As the CFO of Relmada Therapeutics, Inc., Mr. Shenouda earns $1,010,000.00 per year. The highest earning executive at Relmada Therapeutics is Dr. Sergio Traversa M.B.A., Pharm.D., CEO & Director, who commands a salary of $1,790,000.00 per year. Learn More on Maged Shenouda's salary.

How do I contact Maged Shenouda?

The corporate mailing address for Mr. Shenouda and other Relmada Therapeutics executives is 880 Third Avenue 12th Floor, NEW YORK NY, 10022. Relmada Therapeutics can also be reached via phone at (786) 629-1376 and via email at [email protected]. Learn More on Maged Shenouda's contact information.

Has Maged Shenouda been buying or selling shares of Relmada Therapeutics?

Maged Shenouda has not been actively trading shares of Relmada Therapeutics within the last three months. Most recently, on Wednesday, January 31st, Maged Shenouda bought 6,875 shares of Relmada Therapeutics stock. The stock was acquired at an average cost of $4.06 per share, with a total value of $27,912.50. Following the completion of the transaction, the chief financial officer now directly owns 34,903 shares of the company's stock, valued at $141,706.18. Learn More on Maged Shenouda's trading history.

Who are Relmada Therapeutics' active insiders?

Relmada Therapeutics' insider roster includes Charles Casamento (Director), and Maged Shenouda (CFO). Learn More on Relmada Therapeutics' active insiders.

Are insiders buying or selling shares of Relmada Therapeutics?

In the last twelve months, Relmada Therapeutics insiders bought shares 6 times. They purchased a total of 101,176 shares worth more than $382,104.61. The most recent insider tranaction occured on January, 31st when CEO Sergio Traversa bought 27,460 shares worth more than $109,840.00. Insiders at Relmada Therapeutics own 13.5% of the company. Learn More about insider trades at Relmada Therapeutics.

Information on this page was last updated on 1/31/2024.

Maged Shenouda Insider Trading History at Relmada Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2024Buy6,875$4.06$27,912.5034,903View SEC Filing Icon  
1/29/2024Buy10,800$3.65$39,420.0013,028View SEC Filing Icon  
3/10/2021Sell2,373$35.11$83,316.0312,228View SEC Filing Icon  
3/8/2021Sell100$35.00$3,500.0012,228View SEC Filing Icon  
2/10/2021Sell2,410$35.20$84,832.0013,600View SEC Filing Icon  
2/8/2021Sell3,603$35.04$126,249.1213,600View SEC Filing Icon  
2/3/2021Sell3,200$35.04$112,128.005,428View SEC Filing Icon  
1/27/2021Sell3,000$31.93$95,790.005,228View SEC Filing Icon  
1/25/2021Sell1,280$35.27$45,145.606,228View SEC Filing Icon  
1/22/2021Sell2,113$35.55$75,117.156,228View SEC Filing Icon  
12/15/2015Buy3,000$2.99$8,970.005,000View SEC Filing Icon  
See Full Table

Maged Shenouda Buying and Selling Activity at Relmada Therapeutics

This chart shows Maged Shenouda's buying and selling at Relmada Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Relmada Therapeutics Company Overview

Relmada Therapeutics logo
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Read More

Today's Range

Now: $3.70
Low: $3.66
High: $3.81

50 Day Range

MA: $5.17
Low: $3.86
High: $6.80

2 Week Range

Now: $3.70
Low: $2.36
High: $7.22

Volume

85,873 shs

Average Volume

249,252 shs

Market Capitalization

$111.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19